PMID- 12814864
OWN - NLM
STAT- MEDLINE
DCOM- 20030725
LR  - 20190815
IS  - 0006-3223 (Print)
IS  - 0006-3223 (Linking)
VI  - 53
IP  - 12
DP  - 2003 Jun 15
TI  - Elevated cerebrospinal fluid SNAP-25 in schizophrenia.
PG  - 1132-7
AB  - BACKGROUND: Research suggests an association between abnormal exocytosis and 
      schizophrenia. We previously demonstrated increased synaptosomal associated 
      protein, 25 kDa (SNAP-25), a member of the exocytotic mechanism, in the 
      cerebrospinal fluid (CSF) of schizophrenia subjects. In this study, we explored 
      SNAP-25 level and clinical variables in a new group of subjects. METHODS: 
      Twenty-five haloperidol-treated subjects with chronic schizophrenia and 
      twenty-five healthy control subjects participated in the study. Subjects received 
      haloperidol treatment for at least 3 months and then had a lumbar puncture (n = 
      19). Medication was replaced by placebo, and the lumbar puncture was repeated (n 
      = 25) after 6 weeks or sooner if limited psychotic symptoms occurred. We measured 
      the level of SNAP-25 in the CSF and symptoms with the Brief Psychiatric Rating 
      Scale (BPRS). RESULTS: In both haloperidol (p =.001) and placebo (p =.001) 
      treatment conditions, SNAP-25 was elevated. There was no significant difference 
      in SNAP-25 level between conditions. We identified significant positive 
      correlations among SNAP-25 and the BPRS total score and psychosis and thinking 
      disturbance subscales in subjects on haloperidol. CONCLUSIONS: These observations 
      confirm our previous report of elevated CSF SNAP-25 and suggest that synaptic 
      pathology may be linked with the pathophysiology of schizophrenia.
FAU - Thompson, Peter M
AU  - Thompson PM
AD  - Department of Psychiatry, University of Texas Health Science Center at San 
      Antonio, San Antonio, Texas 78229, USA.
FAU - Kelley, Mary
AU  - Kelley M
FAU - Yao, Jeffrey
AU  - Yao J
FAU - Tsai, Guochuan
AU  - Tsai G
FAU - van Kammen, Daniel P
AU  - van Kammen DP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biol Psychiatry
JT  - Biological psychiatry
JID - 0213264
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Membrane Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (SNAP25 protein, human)
RN  - 0 (Synaptosomal-Associated Protein 25)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/administration & dosage
MH  - Biomarkers/cerebrospinal fluid
MH  - Case-Control Studies
MH  - Dopamine Antagonists/administration & dosage
MH  - Exocytosis
MH  - Haloperidol/administration & dosage
MH  - Humans
MH  - Membrane Proteins/*cerebrospinal fluid
MH  - Middle Aged
MH  - Nerve Tissue Proteins/*cerebrospinal fluid
MH  - Psychiatric Status Rating Scales
MH  - Schizophrenia/*cerebrospinal fluid/drug therapy/physiopathology
MH  - Spinal Puncture
MH  - Synaptic Transmission
MH  - Synaptosomal-Associated Protein 25
EDAT- 2003/06/20 05:00
MHDA- 2003/07/26 05:00
CRDT- 2003/06/20 05:00
PHST- 2003/06/20 05:00 [pubmed]
PHST- 2003/07/26 05:00 [medline]
PHST- 2003/06/20 05:00 [entrez]
AID - S0006322302015998 [pii]
AID - 10.1016/s0006-3223(02)01599-8 [doi]
PST - ppublish
SO  - Biol Psychiatry. 2003 Jun 15;53(12):1132-7. doi: 10.1016/s0006-3223(02)01599-8.